Image 5_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg

Image 5_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg

Introduction<p>Oropharyngeal squamous cell carcinoma (OPC) associated with high-risk human papillomavirus (HPV), particularly HPV-16, generally shows favorable outcomes yet paradoxically exhibits a high incidence of early lymphatic metastasis. The immune mechanisms underlying this phenomenon r...

保存先:

書誌詳細
第一著者:	Naohiro Wakisaka (407153) (author)
その他の著者:	Makiko Moriyama-Kita (833101) (author), Satoru Kondo (407152) (author), Eiji Kobayashi (107710) (author), Takayoshi Ueno (457816) (author), Yosuke Nakanishi (407151) (author), Kazuhira Endo (407155) (author), Hisashi Sugimoto (2146888) (author), Tomokazu Yoshizaki (407160) (author)
出版事項:	2025
主題:	Oncology and Carcinogenesis not elsewhere classified HPV-positive oropharyngeal cancer palatine tonsil spatial transcriptomics tumor immune microenvironment Th2 immunity lymphatic metastasis eosinophils and mast cells estrogen signaling
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Image 4_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
著者:: Naohiro Wakisaka (407153)
出版事項: (2025)

Image 2_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
著者:: Naohiro Wakisaka (407153)
出版事項: (2025)

Image 3_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
著者:: Naohiro Wakisaka (407153)
出版事項: (2025)

Image 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.jpeg
著者:: Naohiro Wakisaka (407153)
出版事項: (2025)

Table 1_Exploratory spatial transcriptomic profiling of peritumoral Th2 immune polarization in HPV-positive oropharyngeal cancer.xlsx
著者:: Naohiro Wakisaka (407153)
出版事項: (2025)

Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
著者:: Anna Starshinova (22571846)
出版事項: (2025)

Substrate recognition diversity and transport dynamics of ABCC1
著者:: Pu Gao (14074898)
出版事項: (2025)

Supplementary Figure S1 from Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance
著者:: Glenn J. Hanna (15036909)
出版事項: (2025)

Data Sheet 10_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
著者:: Huiping Fan (13921872)
出版事項: (2025)

Data Sheet 9_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
著者:: Huiping Fan (13921872)
出版事項: (2025)

Data Sheet 8_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
著者:: Huiping Fan (13921872)
出版事項: (2025)

Data Sheet 6_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
著者:: Huiping Fan (13921872)
出版事項: (2025)

Data Sheet 7_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
著者:: Huiping Fan (13921872)
出版事項: (2025)

Data Sheet 5_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
著者:: Huiping Fan (13921872)
出版事項: (2025)

Data Sheet 4_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
著者:: Huiping Fan (13921872)
出版事項: (2025)

Data Sheet 3_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
著者:: Huiping Fan (13921872)
出版事項: (2025)

Data Sheet 2_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
著者:: Huiping Fan (13921872)
出版事項: (2025)

Data Sheet 1_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
著者:: Huiping Fan (13921872)
出版事項: (2025)

Microbiome Mediated Immune Crosstalk on the Gut-Thyroid Axis in Autoimmune Thyroid Disease
著者:: Mubeen Hussein Arawker (12965954)
出版事項: (2025)

Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
著者:: Seyed Reza Mousavi (13223324)
出版事項: (2025)

Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
著者:: Seyed Reza Mousavi (13223324)
出版事項: (2025)

Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
著者:: Seyed Reza Mousavi (13223324)
出版事項: (2025)

The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
著者:: Seyed Reza Mousavi (13223324)
出版事項: (2025)

Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
著者:: Seyed Reza Mousavi (13223324)
出版事項: (2025)

Survey of dysphagia protocol use (Carnaby et al., 2025)
著者:: Giselle D. Carnaby (22575401)
出版事項: (2025)

Image 2_Immune-related RELT drives clear cell renal cell carcinoma progression through JAK/STAT signaling pathway activation.tiff
著者:: Yini Wang (410389)
出版事項: (2025)

Image 1_Immune-related RELT drives clear cell renal cell carcinoma progression through JAK/STAT signaling pathway activation.tiff
著者:: Yini Wang (410389)
出版事項: (2025)

Lipids attribution for controls and dengue groups according with Lipid Maps database, obtained via exploratory metabolomics from human serum.
著者:: Ricardo E. Correa Fierro (22676430)
出版事項: (2025)

Table 1_Immune checkpoint inhibitor therapy in advanced cancer: clinical association of irAEs type, inflammatory markers and efficacy.docx
著者:: Mengying Qian (2541466)
出版事項: (2025)

Table S2 from Hydrogen Sulfide Creates a Favorable Immune Microenvironment for Colon Cancer
著者:: Taohua Yue (14963045)
出版事項: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
著者:: Yu Chen (1234761)
出版事項: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
著者:: Yu Chen (1234761)
出版事項: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
著者:: Yu Chen (1234761)
出版事項: (2025)

Supplementary Table from CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses
著者:: Yu Chen (1234761)
出版事項: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
著者:: Isha Mondal (16721699)
出版事項: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
著者:: Kankan Cao (16437263)
出版事項: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
著者:: Hansol Lee (15054787)
出版事項: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
著者:: Hansol Lee (15054787)
出版事項: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
著者:: Hansol Lee (15054787)
出版事項: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
著者:: Hansol Lee (15054787)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_k9g75usqeanq1hbf093hs87815